Selected Bibiliography

Grandori, C. and Kemp, C.J. Personalized cancer models for target discovery and precision medicine. Trends in Cancer, in press, 2018.

Xu, C.*, Nikolova, O.*, Basom, R.S., Mitchell, R.M., Shaw, R., Moser, R.D., Park, H., Gurley, K.E., Kao, K.C., Green, C.L., Schaub, F.Z., Diaz, R.L., Swan, H.S., Jang, I.S., Guinney, J., Gadi, V.K., Margolin, A.A.,  Grandori, C., Kemp, C.J., Méndez, E., § (*co-first authors; §co-corresponding authors).  Functional precision medicine identifies novel targets and therapeutic options in head and neck cancer. Clin. Cancer Res., 24, 2828-2843, 2018.

Ashley, A.K., Kemp, C.J. Etiology of Cancer: Chemical Factors. In: Cancer Principles and Practice of Oncology, DeVita, V.T., Lawrence, T. S., and Rosenberg, S.A., Eds. Walters Kluwer, in press, 2018.

Gurley, K.E., Ashley, A. K., Moser, R., and Kemp, C.J. Synergy between Prkdc and Trp53 regulates stem cell proliferation and GI-ARS after irradiation. Cell Death and Differentiation, 24, 1853-1860, 2017.

Pauli C., Hopkins B., Prandi D., Shaw R., Fedrizzi T., Sboner A., Sailer V., Augello M., Puca L., Rosati R., McNary T., Churakova Y., Cheung C., Triscott J., Pisapia D., Rao R., Mosquera J.M., Robinson B., Faltas B., Emerling B., Gadi V.K., Bernard B., Elemento O., Beltran H., Dimichelis F., Kemp C.J., Grandori C., Cantley L., Rubin M., Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discovery 7 (5) 462-77, 2017.

Westcott, P.M.K.,  Halliwill, K.D., To, M.d., Mamunar, R., Rust, A.G., Keane, T.M., Delrosario, R., Jen, K.U.,  Gurley, K.E., Kemp, C.J., Fredlund, E., Quigley, D.A., Adams, D.J., Balmain, A., The mutational landscapes of genetic and chemical models of Kras-driven non-small cell lung cancer.  Nature, 517, 489-492, 2015.

Moser, R., Xu, C., Kao, M., Annis, J., Lerma, L.A., Schaupp, C., Gurley, K.E., Jang, I.S., Margolin, A., Biktasova, A., Yarbrough, W.G., Grandori, C., Kemp, C.J., and Mendez, E.  Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin. Cancer Res., 20, 4274-4288, 2014.

Moore, J. M., Moser, R., Bernard, B., Teater, M., Smith, L. E., Rabaia, N., Gurley, K., Guiney, J., Busch, S.E.,  Shaknovich, R., Lobanenkov, V.V.,  Liggitt, D., Shmulevich, I., Melnick A., and Filippova, G.N. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Reports, 7, 1020-1029, 2014.

Busch, S.E., Gurley, K.E., Moser, R., Kelly-Spratt, K.S., Liggitt, D., and Kemp, C.J.  p19Arf inhibits the growth and malignant progression of carcinogen induced non small cell lung cancer.  Oncogene, 33: 2665-2673, 2014.

Kemp, C.J. Animal models of chemical carcinogenesis: driving breakthroughs in cancer research for 100 years. In: Mouse Models of Cancer, C. Abate-Shen, K. Politi, K.P. Olive, and L. Chodosh, Eds. Cold Spring Harbor Laboratory Press, pgs 51-60, 2013.

Kemp, C.J. and Grandori, C. Functional genomics to identify unforeseen cancer drug targets. Future Oncol. 9: 473-476, 2013. 

Fero, M.L., Randel, E., Gurley, K.E., Roberts, J. and Kemp, C.J.   The murine gene p27/Kip1 is haploinsufficient for tumour suppression.  Nature 396:177-180, 1998.